USPTO Art Unit 1617 Prosecution Statistics

Art Unit Information

Art Unit: 1617
Group: 1610
Tech Center: 1600
Total Cases: 15,020
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19025668METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONJanuary 2025April 2025Allow310YesNo
18967829Formulations of EnzalutamideDecember 2024May 2025Allow610YesNo
18962073BURN WOUND TREATMENTNovember 2024April 2025Allow511NoNo
18950997CANCER TREATMENT METHOD WITH NANOCOMPOSITENovember 2024January 2025Allow210NoNo
18913776DOUBLE-NETWORK VERSATILE HYDROGEL WITH ANTIBACTERIAL AND DRUG SEQUENTIAL RELEASE CAPABILITIESOctober 2024February 2025Allow510NoNo
18911121METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTIONOctober 2024May 2025Allow711YesNo
18910243SKINCARE COOLING PRODUCT, METHOD OF MAKING, AND METHOD OF USING THE SAMEOctober 2024April 2025Allow611YesNo
18898561ANTIBACTERIAL CONDUCTIVE SELF-HEALING HYDROGELSeptember 2024December 2024Allow200NoNo
18893280COMPOSITIONS AND METHODS FOR DELIVERY OF RNASeptember 2024June 2025Allow910NoNo
18891739ION CHANNEL PROSTHETIC COMPOSITIONS COMPRISING LIPID-COATED CRYSTALS OF AMPHOTERICIN BSeptember 2024May 2025Allow821NoNo
18795731COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795683COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795711COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795653Surfactin-Based Lipopeptide for mRNA DeliveryAugust 2024February 2025Allow610YesNo
18795667Surfactin-Based Lipopeptide for mRNA DeliveryAugust 2024February 2025Allow610NoNo
18792849Methods of administering safe colon cleansing compositionsAugust 2024February 2025Allow710NoNo
18793091Herbicidal compositions comprising trifludimoxazinAugust 2024September 2024Allow200YesNo
18778340SYNTHESIS AND CHARACTERIZATION OF GLAUCONITE-BASED SILICATE NANORODS AS ANTICANCER AGENTJuly 2024October 2024Allow310YesNo
18765361MAGNETIC NANO-DRUG WITH DOUBLE TARGETING VEGF-VEGFR, AND PREPARATION METHOD AND APPLICATION THEREOFJuly 2024December 2024Allow511NoNo
18758007COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAJune 2024December 2024Allow610NoNo
18720721EFFECT PIGMENTS HAVING A REFLECTIVE CORE AND SEMICONDUCTOR LAYERSJune 2024March 2025Allow910NoNo
18743526Methods of administering safe colon cleansing compositionsJune 2024December 2024Allow720YesNo
18739871HORTICULTURAL HYDROGELSJune 2024December 2024Allow620NoNo
18736965OLANZAPINE COMPOSITIONS AND METHODS OF USEJune 2024December 2024Allow611NoNo
18711575INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USEMay 2024May 2025Allow1211YesNo
18664867METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTIONMay 2024March 2025Allow1011YesNo
18662099Surfactin-Based Lipopeptide for mRNA DeliveryMay 2024November 2024Allow611NoNo
18660885BLETILLA STRIATA POLYSACCHARIDE IRON COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2024March 2025Abandon1011NoNo
18659629AQUEOUS LIQUID PREPARATIONMay 2024January 2025Allow811YesNo
18703622PERFUMING COMPLEX, PERFUMING COMPOSITION AND PERFUMED AQUEOUS COMPOSITION OF NATURAL ORIGINApril 2024March 2025Allow1010NoNo
18629707METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERYApril 2024June 2025Allow1412YesNo
18626374USE OF DESTRUCTURIZED STARCH AS A THICKENING AGENT AND COMPOSITIONS CONTAINING ITApril 2024June 2025Abandon1510NoNo
18623761COMPACTABLE ORAL FORMULATIONS OF IBUTAMORENApril 2024June 2025Allow1421YesNo
18609954MULTI-LAYERED POLYMER FILM FOR SUSTAINED RELEASE OF AGENTSMarch 2024February 2025Allow1110YesNo
186070935-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONSMarch 2024September 2024Allow601NoNo
18606877Pharmaceutical Complex for Radioprotection, Preparation Method, and Applications thereofMarch 2024May 2025Abandon1421NoNo
18602676ADIPOSE TISSUE MATRICESMarch 2024April 2025Abandon1310NoNo
18593225MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEENMarch 2024February 2025Allow1110YesNo
18582837POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHERFebruary 2024April 2025Allow1411YesNo
18581460Treatment of Vomiting and Nausea with Minimum Dose of OlanzapineFebruary 2024April 2025Allow1310NoNo
18444485Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereofFebruary 2024April 2025Allow1421NoNo
18443689NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024May 2024Allow300YesNo
18433701METHOD FOR CONTROLLING THE GROWTH OF UNDESIRABLE VEGETATIONFebruary 2024March 2025Abandon1301NoNo
18430003NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024January 2025Abandon1110NoNo
18429056DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOFJanuary 2024July 2024Allow511YesNo
18425024GRANULATED AGRICULTURAL ADJUVANT AND METHOD OF MAKING AND USING SAMEJanuary 2024January 2025Allow1110NoNo
18423852MULTI-LAYER HAEMOSTAT PATCH COMPRISING BETA-CHITINJanuary 2024June 2025Abandon1611NoNo
18421405LOSARTAN LIQUID FORMULATIONS AND METHODS OF USEJanuary 2024July 2024Allow610YesNo
18290914STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOFJanuary 2024March 2025Allow1311YesNo
18417945NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSJanuary 2024December 2024Allow1021YesNo
18417989NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONSJanuary 2024May 2025Abandon1621NoNo
18416354THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USEJanuary 2024December 2024Allow1110NoNo
18411935Method of Preventing and Treating COVID-19 InfectionJanuary 2024April 2025Abandon1510NoNo
18405767ANTIMICROBIAL ENHANCEMENT OF CATIONIC ACTIVE SKIN ANTISEPTICSJanuary 2024February 2025Allow1310NoNo
18405543Compacted Hemostatic Cellulosic AggregatesJanuary 2024July 2024Allow700YesNo
18400346ORALLY AVAILABLE ARTICLES CONTAINING AT LEAST ONE STABILIZED SUPPLEMENT THEREINDecember 2023December 2024Allow1101NoNo
18575043COMPOSITE, MANUFACTURING METHOD THEREFOR, AND COSMETIC SURGERY FILLER COMPOSITION USING SAMEDecember 2023March 2025Allow1521NoNo
18393184PROTOPORPHYRINOGEN OXIDASE INHIBITORSDecember 2023January 2025Allow1310NoNo
18390700COMPOSITIONS AND METHODS FOR DELIVERY OF RNADecember 2023June 2024Allow610NoNo
18541510PHARMACEUTICAL COMPOSITIONS FOR VAPORIZATION AND INHALATIONDecember 2023October 2024Abandon1001NoNo
18542163PHARMACEUTICAL LIQUID COMPOSITIONS OF MELOXICAMDecember 2023February 2025Allow1420YesYes
18538617DETERGENT COMPOSITIONS FOR WASHING URUSHIOL AND METHODS OF TREATING URUSHIOL INDUCED CONTACT DERMATITISDecember 2023February 2025Allow1410NoNo
18534062SILVER NANOPARTICLE COMPOSITION INCLUDING BIOSYNTHESIZED SILVER NANOPARTICLES AND AN EXTRACT OF FARSETIA AEGYPTIACADecember 2023July 2024Allow711YesNo
18533079CHITOSAN FILM WITH TERNARY METAL OXIDESDecember 2023March 2024Allow301YesNo
18533083CHITOSAN FILM WITH TERNARY METAL OXIDESDecember 2023March 2024Allow301YesNo
18523274PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBNovember 2023April 2025Abandon1611NoNo
18518100COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023February 2024Allow310NoNo
18518110COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023March 2024Allow400YesNo
18518093COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023April 2024Allow410NoNo
18506204ACTIVE AGENT-CONTAINING MATRIX PARTICLES AND PROCESSES FOR MAKING SAMENovember 2023January 2025Abandon1410NoNo
18387552PYRIDINO-2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow401NoNo
18501955LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDESNovember 2023July 2024Allow911YesNo
18501950LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDESNovember 2023March 2025Allow1710NoNo
18501958LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDESNovember 2023May 2024Allow601YesNo
18501945LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDESNovember 2023March 2025Allow1720NoNo
18498005MANUFACTURING METHOD OF CASINGOctober 2023March 2025Abandon1610YesNo
18384288Method for Synthesizing Silver Nanoparticles from Amaranthus hybridusOctober 2023August 2024Allow1021NoNo
18384214Method for Synthesizing Silver Nanoparticles from Amaranthus hybridusOctober 2023June 2024Allow811YesNo
18491407C-Met Modulator Pharmaceutical CompositionsOctober 2023January 2025Abandon1510NoNo
18490197COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAOctober 2023January 2024Allow200YesNo
18490188COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAOctober 2023January 2024Allow300YesNo
18381402COMPOUND, A CONJUGATE AND USES THEREOFOctober 2023July 2024Allow911NoNo
18488513AMORPHOUS SOLID DISPERSIONSOctober 2023September 2024Allow1110YesNo
18286774ANTIMICROBIAL COMPOSITIONOctober 2023March 2025Abandon1720NoNo
18482612TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USEOctober 2023January 2024Allow300NoNo
18481946PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATEOctober 2023January 2024Allow411YesNo
18373774COMBINATION THERAPYSeptember 2023June 2025Abandon2101NoNo
18474052MINOXIDIL ADJUVANT THERAPIESSeptember 2023April 2025Abandon1810NoNo
18370457DELIVERY SYSTEM DEVICE AND METHOD FOR PHARMACEUTICAL IMPLANTATION FOR TIMED RELEASESeptember 2023December 2024Allow1520YesNo
18470280COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERYSeptember 2023December 2024Allow1421NoNo
18470327ENCAPSULATION OF GASTRIC RESIDENCE SYSTEMSSeptember 2023December 2024Allow1420YesNo
18282545A composition for use in the treatment of urinary or faecal incontinenceSeptember 2023December 2024Allow1511YesNo
18468199AMORPHOUS SOLID DISPERSIONSSeptember 2023April 2025Allow1911NoNo
18467858TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONSeptember 2023December 2024Allow1510NoNo
18464906MAKEUP COMPOSITIONS FOR TREATING SKIN DEFECTSSeptember 2023March 2025Abandon1801NoNo
18281326USE OF APPLICATION MODE OF TRICHODERMA HARZIANUM (T. HARZIANUM) IN GROWTH AND INDUCED RESISTANCE OF NICOTIANA TABACUM (N. TABACUM)September 2023June 2024Allow910YesNo
18243740RECTAL ADMINISTRATION OF ROFLUMILAST FOR THE TREATMENT OF CROHN'S DISEASESeptember 2023May 2024Abandon820NoNo
18462292COMPOSITIONS USING IRON EXCIPIENTS AND THEIR USES INCLUDING FOR THE TREATMENT OF CANCERSeptember 2023June 2025Allow2130NoNo
18242468CARBOHYDRATE CROSSLINKERSeptember 2023April 2025Abandon2030YesNo
18458973COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLSAugust 2023March 2024Allow711YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1617.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
503
Examiner Affirmed
350
(69.6%)
Examiner Reversed
153
(30.4%)
Reversal Percentile
40.9%
Lower than average

What This Means

With a 30.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
2135
Allowed After Appeal Filing
492
(23.0%)
Not Allowed After Appeal Filing
1643
(77.0%)
Filing Benefit Percentile
11.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1617 - Prosecution Statistics Summary

Executive Summary

Art Unit 1617 is part of Group 1610 in Technology Center 1600. This art unit has examined 15,020 patent applications in our dataset, with an overall allowance rate of 46.6%. Applications typically reach final disposition in approximately 34 months.

Comparative Analysis

Art Unit 1617's allowance rate of 46.6% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1617 receive an average of 2.27 office actions before reaching final disposition (in the 83% percentile). The median prosecution time is 34 months (in the 23% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.